Gunther Birznieks
CIK: 0001702031
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Vanda Pharmaceuticals Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Mar 2, 2026VNDA
Vanda Pharmaceuticals Inc.
Sale(S)Direct42.4K shares at avg. $8.27$351K - Feb 18, 2026VNDA
Vanda Pharmaceuticals Inc.
Award(A)Direct125K shares- - Mar 1, 2025VNDA
Vanda Pharmaceuticals Inc.
Tax Payment(F)Direct26.9K shares at avg. $4.76$128K - Feb 18, 2025VNDA
Vanda Pharmaceuticals Inc.
Award(A)Direct125K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 2, 2026 | VNDA Vanda Pharmaceuticals Inc. | Sale(S) | 42,431 | $8.27 | $350,730 | Direct |
| Feb 18, 2026 | VNDA Vanda Pharmaceuticals Inc. | Award(A) | 125,000 | - | $0 | Direct |
| Mar 1, 2025 | VNDA Vanda Pharmaceuticals Inc. | Tax Payment(F) | 26,941 | $4.76 | $128,239 | Direct |
| Feb 18, 2025 | VNDA Vanda Pharmaceuticals Inc. | Award(A) | 125,000 | - | - | Direct |
1-4 of 4 transactions
About Birznieks Gunther
Birznieks Gunther (SEC CIK 0001702031) files insider reports with the SEC as SVP, Business Development of Vanda Pharmaceuticals Inc. (VNDA).
Signal8 holds 4 ownership filings by Birznieks Gunther, all Form 4s, filed between Feb 20, 2025 and Mar 4, 2026. Those filings report 4 transactions, from Feb 18, 2025 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Birznieks Gunther's filings is in WASHINGTON, DC.
Recent filings by Birznieks Gunther
Other insiders filing for Vanda Pharmaceuticals Inc. (VNDA)
- McGuire Daniel Patrick, SVP, GC and Secretary
- Chrousos Phaedra, Director
- Duncan Charles Cliff, Director
- DUGAN RICHARD W, Director
- Ward Anne Sempowski, Director
- Honore Tage, Director